11 / 11
Note:
Page 39
April 11-12, 2019 | Barcelona, Spain
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Neuroscience Congress 2019
Journal of Neurology and Neurorehabilitation Research | Volume 4
NEUROSCIENCE AND
NEUROLOGICAL DISORDERS
2
nd
International Conference on
INVESTIGATING THE ANTI-INFLAMMATORY EFFECTS OF A NOVEL NOOTROPIC IN
GLIAL CELLS EXPOSED TO ANTI-RETROVIRAL THERAPY
Helena Isla Magrane
Brighton University, UK
N
euroinflammation is a process that can be observed not only in neurodegenerative diseases but also as a
result of infection alterations in the brain. The infection agent, or the drugs used to treat the pathology, can
lead to neuroinflammation. The neuroinflammatory effects of different drugs used to treat HIV have not been
investigated yet. The aim of this project is to test the inflammatory effects of anti retroviral drugs used to treat
HIV patients in brain cell cultures. Once the cause of the inflammation is known, the decision on which drug to
use, for each particular case, will be easier to make. In the case of patients with neuroinflammation, some an-
ti-retroviral drugs – expected to be less inflammatory – can be used. Furthermore, a nootropic drug was tested.
This could play an important role in helping to cope with the inflammation. To test the inflammatory effects
of the drugs, we used microglia and astrocyte in vitro models. Glial cells and astrocytes can secrete or respond
with a variety of cytokines. IL 1 β, IL-6 and TNF-α, are cytokines used as markers for inflammation. In this study,
the ability of mixed glial cells and astrocytes to secrete IL-1 β, IL-6 and TNF-α in response to three anti-retroviral
drugs (maraviroc, efavirenz and rilpivirine) has been examined. Loss of memory is one of the consequences
in later stages in HIV. Sunifiram, a novel nootropic drug, is believed to help with inflammation and to improve
cognition. The pro inflammatory or anti-inflammatory effect of Sunifiram on astrocyte cultures, combined with
the anti-inflammatory drug treatments, was tested.
Helena Isla Magrane, J Neurol Neurorehabil Res 2019, Volume 4
Helena Isla Magrane is a Biothechnologist who performed a master research bioscience in Brighton University (UK). Focused her
master thesis on neuroscience area. Gained a lot of experience on reasearch, investigated the anti-inflammatoey effects of a novel
nootropic drug in glial cells exposed to anti-retroviral therapy, carried out the project in collaboration with Imperial College of Lon-
don. potential problem solver and very passioned on her work as she love science.
H.Isla@brighton.ac.ukBIOGRAPHY